Tissue-repair, gut & immune-signalling peptides
Teriparatide
Also known as PTH(1-34) · Forteo · Forsteo
The 1–34 fragment of human parathyroid hormone — the first bone-building (anabolic) osteoporosis medicine.
In 60 seconds
Approved for severe osteoporosis in many countries (prescription-only). Reviews document hypercalcaemia and dizziness; an osteosarcoma signal in rats led to historical duration limits in labelling.
- VERO compared new fractures with teriparatide versus risedronate in severe postmenopausal osteoporosis.
- DATA compared bone-mineral-density gains with teriparatide, denosumab or both combined.
- Reviews teriparatide’s unique bone-forming mechanism compared with antiresorptive agents.
Mechanism
Intermittent, once-daily activation of the PTH1 receptor stimulates osteoblasts more than osteoclasts, building new bone; continuous PTH exposure does the opposite. This timing-dependent effect is why teriparatide is anabolic rather than resorptive.
Research status
Approved for severe osteoporosis in many countries (prescription-only). Head-to-head fracture trials (VERO) and combination studies with denosumab (DATA) are its landmark data.
Key studies
VERO compared new fractures with teriparatide versus risedronate in severe postmenopausal osteoporosis.
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial — Lancet, 2018 · PMID 29129436
DATA compared bone-mineral-density gains with teriparatide, denosumab or both combined.
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial — Lancet, 2013 · PMID 23683600
Reviews teriparatide’s unique bone-forming mechanism compared with antiresorptive agents.
Teriparatide: a review — Clin Ther, 2004 · PMID 15262455
A placebo-controlled trial in 50 patients studied teriparatide after pertrochanteric fracture fixation.
A randomized controlled trial of teriparatide for accelerating bone union and improving clinical outcomes in patients with pertrochanteric fracture fixation — Sci Rep, 2025 · PMID 40461584
Safety signals in the literature
Reviews document hypercalcaemia and dizziness; an osteosarcoma signal in rats led to historical duration limits in labelling.
Legal status (South Africa)
Not registered as a medicine for human use in South Africa (unless stated otherwise); research use only.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Teriparatide and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Teriparatide
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Teriparatide?
The 1–34 fragment of human parathyroid hormone — the first bone-building (anabolic) osteoporosis medicine. Intermittent, once-daily activation of the PTH1 receptor stimulates osteoblasts more than osteoclasts, building new bone; continuous PTH exposure does the opposite. This timing-dependent effect is why teriparatide is anabolic rather than resorptive.
What is the research status of Teriparatide?
Approved for severe osteoporosis in many countries (prescription-only). Head-to-head fracture trials (VERO) and combination studies with denosumab (DATA) are its landmark data.
What safety signals are reported for Teriparatide?
Reviews document hypercalcaemia and dizziness; an osteosarcoma signal in rats led to historical duration limits in labelling.
Does Living Water Labs stock Teriparatide?
Not at present. Teriparatide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Not registered as a medicine for human use in South Africa (unless stated otherwise); research use only.
More in Repair & immune
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
